NCT06255197|RecruitingDMC
Loading search results
Sponsor study identifier
observational
60,000
1 country
1
Study Start
November 4, 2019
Actual (reported)Primary Completion
December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
December 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This study is a multi-center, observational, real-world study for patients with resected lung cancers in China. With the help of a properly designed data processing algorithm and extensively performed data quality assurance, this study aims to harness the potential of real-world big data to (1) describe characteristics and treatment patterns and their evolving trends; (2) discover features associated with overall survival; and (3) address recently-emerging clinical questions.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
November 4, 2019
Actual (reported)February 4, 2024
Actual (reported)February 13, 2024
Actual (reported)December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
December 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Overall survival
Time from surgery to death from any cause.
January 2014 to December 2031
Baseline characteristics of included participants
January 2014 to December 2028
Treatment patterns of included participants
January 2014 to December 2028
Pathological characteristics of included participants
Patients who were diagnosed with lung cancer and received surgical resection in participating medical centers during the designed study period.
Participants eligible for this study would be screened from consecutive patients who received surgical resection for lung malignancies in participating medical centers during the designed study period.
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, Beijing Municipality, 100021, China
Jie He, MD-PhD
National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, CAMS and PUMC
First Submitted
February 4, 2024
First Posted
February 13, 2024
Study Start
November 4, 2019
Actual (reported)Primary Completion
December 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Associated With Chinese Patients With Advanced Lung Cancer
January 2014 to December 2028
Features associated with overall survival
First analysis is anticipated to be performed from April to August 2024; the final analysis is anticipated in 2032.
Contact the study team to confirm eligibility.
Study Completion
December 31, 2031
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
February 16, 2024
Record last verified: 2024-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: